Signature Seminar Series (Virtual): Novel Host Directed Interventions for Prevention and Treatment of Leishmaniasis

Date: 22 June 2020
Time: 10:00 AM - 11:00 AM
Venue: Zoom
Audience: Healthcare Professionals
Cost:

The leishmaniasis is a WHO designated neglected tropical disease. More than 350 million people worldwide are at risk of contracting leishmaniasis. Current treatments for all forms of leishmaniasis are lengthy, and highly toxic. Besides safety concerns with current medication, drug resistant parasites are becoming more and more commonplace. Clearly new treatments and a vaccine for leishmaniasis is needed. Host directed therapy (HDT) is a viable alternative which targets the host pathways responsible for parasite survival and pathogenicity. HDT has gained significant momentum with the recent innovative combinations of different genomics, proteomics and computational biology approaches. Given the success of HDT in the field of cancer and autoimmunity, there is potential for its employment in treating infectious diseases. This talk will be an overview of translational research by our team that has led to discovery of novel host directed treatments and development of a vaccine using CRISPR technology for leishmaniasis.

Speaker Details

Prof Abhay R Satoskar MD, PhD, Professor and Vice Chair for Research, Dept of Pathology, Ohio State University

Dr. Satoskar completed medical schooling from University of Mumbai followed by training in Pathology. He did a fellowship at Max Planck Institute for Immunobiology and a PhD from University of Strathclyde UK. He then joined as a Research Fellow in the Department of Immunology and Infectious Diseases at Harvard School of Public Health. Dr. Satoskar was recruited to the Ohio State University as a faculty in 2001. He is currently Professor and Vice Chair in the Department of Pathology.

Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.